As with so much of Lilly’s recent advertising work, Wieden+Kennedy’s specific style and tone have helped differentiate its commercials from that of other pharma companies.

In fact, last year Lilly's medication -- called tirzepatide, which treats both type 2 diabetes and obesity -- became the best ...

Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.

This history of rapid acceleration suggests that Eli Lilly is primed for another massive breakout as new catalysts emerge.

By Padmanabhan Ananthan and Sriparna Roy Feb 9 (Reuters) - Eli Lilly will buy Orna Therapeutics for up to $2.4 billion in ...

Eli Lilly and Innovent Biologics have deepened their ties with a new type of deal. | Eli Lilly and Innovent Biologics have ...

SHANGHAI, Feb 11 (Reuters) - Eli Lilly has won Chinese regulators' approval for its drug to treat chronic inflammatory bowel ...

Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders. | Eli Lilly ...

Orna Therapeutics, which engineers immune cells inside the body, will fold into one of the world’s largest drugmakers. The post Eli Lilly snaps up Watertown biotech in $2.4 billion deal appeared first ...

Eli Lilly and Company (NYSE:LLY) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 9, Eli Lilly and ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug ahead of an expected decision by the U.S. Food and Drug Administration in April, Reuters writes, ...